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tions. Extrapolating to national data, it is estimated that more than €14 billion were
paid for AEDs in off-label use (more than €13 billion paid by the NHS).
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OBJECTIVES: Multiple sclerosis (MS) is a chronic inflammatory disease with 12,000
new diagnoses per year in the United States. Higher latitude is associated with
higher MS prevalence rates, and the female-to-male ratio in MS incidence has been
estimated at 2:3 in 2000. This study aims to estimate the prevalence and incidence
rate of MS in the United States. METHODS: Patients with an MS diagnosis (Inter-
national Classification of Diseases Ninth Revision Clinical Modification [ICD-9-CM]
code: 340.XX) between January 2006 and December 2010 were identified from a
large U.S. claims database. Prevalence rates from 2006 to 2010 were calculated by
dividing the number of MS patients by the total number of health plan enrollees in
each year. The 2010 incidence rate was calculated by dividing the number of pa-
tients with a new MS diagnosis in 2010 by the total number of enrollees in 2010.
RESULTS: The prevalence rate remained stable at 0.16% from 2006 to 2008, and
then increased in 2009 (0.17%) and again in 2010 (0.19%). In 2010, MS prevalence in
women (0.26%) was more than twice the rate than that of the male population
(0.09%). To examine regional differences, prevalence rate was also calculated for
each U.S. state. Regional prevalence rates ranged from 0.11% (Arkansas) to 0.29%
(Rhode Island). The estimated incidence rate for 2010 was 0.03% for the overall
population, 0.05% for female, and 0.02% for male patients. Incident cases had an
average age of 49 years, and were more likely to suffer from comorbid conditions,
such as disturbance of skin sensation, fatigue, and hypertension. Incidence rates
by state ranged from 0.01% (Maine) to 0.08% (Michigan). CONCLUSIONS: This study
confirms that MS prevalence and incidence rates are higher in female patients, and
in regions farther away from the equator.
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OBJECTIVES: One important aspect for patients suffering from multiple sclerosis
(MS) is the frequency and severity of relapses that lead to a significant increase in
symptoms and an aggravation of health related quality of life. In this study, data of
about 3,000 MS patients have been analysed over a five year period in order to
identify the number of relapses and the events that may follow a relapse.
METHODS: Information was taken from 2006 to 2010 German claims data. To iden-
tify a relapse, several indicators such as hospitalisations, specific relapse medica-
tion and outpatient consultations have been investigated. RESULTS: The results
show that the identification of relapses can be achieved by including inpatient,
outpatient and relapse medication data. Relapses were found for 47% of all MS
patients. Among those receiving MS medication, 67% suffered from relapses while
only 32% of the patients without medication were affected. This may indicate that
the proportion of patients having a higher risk of relapses is usually under MS-
treatment. Most patients with relapses (64%) did not show more than three re-
lapses within five years. The events following a relapse were classified by the
number of hospitalisations (14% within one month after the relapse), transitions
from basic to escalating MS medication (3% within one quarter after the relapse) or
changes of disease modifying drug (3% within one quarter after the relapse).
Changes of basic MS medication are not necessarily related to relapses, while
changes from basic to escalating MS medication are often observed after such an
event. CONCLUSIONS: Patients with high frequencies of relapses are treated with
disease modifying drugs more often than other patients. Most of the MS patients do
not suffer from relapses within the observation period of five years, with a small
group of patients suffering from numerous relapses.
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OBJECTIVES: To explore the impact of severity and rate of decline of cognitive
impairment on mortality within Alzheimer’s disease (AD) patients. METHODS:
Data on AD patients were from CERAD (Consortium to Establish a Registry for
Alzheimer’s Disease), a US multicenter, longitudinal study. Patient demographics,
cardiovascular and other co-morbidities, activities of daily living (ADL), cognitive
impairment measured by the Mini-Mental State Examination (MMSE) and Clinical
Dementia Rating (CDR), and survival status were obtained at study entry (baseline),
and at annual follow-up visits. Study survival time was modelled as a function of
patient baseline demographics, cognitive impairment at entry and its decline over
time using parametric survival models and semi-parametric Cox proportional haz-
ard model (PH), with decline of cognitive impairment as a time-dependent
covariate. RESULTS: 1010 patients with non-missing survival data were included in
the analysis. At baseline, men, age and cognitive impairment significantly in-
creased the mortality risk (p0.001 for all). Additionally, patients progressing to a
more severe stage of cognition over time had significantly higher mortality risk
(p0.001), with a hazard ratio for CDR change over time versus baseline as a time
dependent covariate of 1.35 [95% CI: 1.21-1.51]. CDR and MMSE scores were highly
correlated; results based on models using either CDR or MMSE were mostly consis-
tent. Results were confirmed by sensitivity analyses with varying modelling
assumptions. CONCLUSIONS: Severity and rate of decline of cognitive impairment
are both strong predictors of survival in AD, additional to the usual demographic
and clinical patient characteristics. These findings suggest that treatments delay-
ing the progression of AD patients to more severe stages of cognitive impairment
might positively impact overall survival.
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OBJECTIVES: Cystic fibrosis (CF), the most common lethal genetic disease in Cau-
casians, causes a high burden of disease. Median age at death is in the late 20s with
the most common mode of death being respiratory failure. Treatment with iva-
caftor, a CF transmembrane conductance regulator (CFTR) protein potentiator, was
generally safe and improved risk-factors for mortality in CF, including pulmonary
function, weight and pulmonary exacerbations. Since controlled clinical trials can-
not directly demonstrate survival benefits, we estimated the potential for survival
benefit from drug therapies based on similar, observed short-term changes to risk
factors known to impact survival in CF. METHODS: Survival information for CF
patients in Germany, France, the UK, and Ireland was obtained from national reg-
istries and individually fitted to a Weibull function. From these survival curves the
hazard function for an average CF patient was calculated as a function of age. The
impact to the hazard function from improvements in risk factors (FEV1, weight-
for-age z-score, pancreatic sufficiency, diabetes, Staphylococcus aureus, Burkholderia
cepacia, and annual number of pulmonary exacerbations) was estimated using pre-
viously published Cox proportional hazards model for CF mortality. RESULTS: For
each country, a survival function was developed taking into account current aver-
age mortality rates and estimated long-term changes to risk factors. Sensitivity
analysis suggest that it is possible for drugs that improve clinical outcomes in CF,
including pulmonary function, weight and pulmonary exacerbations, to add a de-
cade to the median life expectancy CF patients. CONCLUSIONS:Modeling suggests
that therapies that improve clinical risk factors for mortality in CF, including pul-
monary function, weight and pulmonary exacerbations, may extend the lives of CF
patients.
NEUROLOGICAL DISORDERS - Cost Studies
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OBJECTIVES: To estimate the economic impact of introducing the test for diagnos-
ing the five cardiopathies associated to SCD related to the currently best known
genes in Spain: 1.Hypertrophic Cardiomyopathy (HCM); 2.Arrhythmogenic Right
Ventricular Cardiomyopathy (ARVC); 3.Long-QT Syndrome (LQTS); 4.Brugada Syn-
drome (BrS), and 5.Catecholaminergic Polymorphic Ventricular Tachycardia
(CPVT). METHODS: A 3-year budget impact analysis was carried out based on in-
ternational sources of epidemiological and health care resource utilization data;
local input costs and market share, and expert opinion. Two scenarios were com-
pared: current clinical practice (with no genetic testing) vs. alternative practice
(with genetic testing). The perspective adopted was that of the Spanish National
Healthcare System (NHS). All costs referred to €, 2012. RESULTS: The target popu-
lation at risk of SCD was estimated on 25,220 patients for year 1; 26,352 for year 2,
and 26,340 for year 3. Genetic testing would be conducted in 350, 550 and 700
patients in 2012, 2013 and 2014, respectively. The budget impact of introducing the
genetic testing would imply an additional cost of € 309,187, € 532,311, and € 724,404,
respectively. Genetic testing compared to current practice would imply cost sav-
ings of € 10,152 and of € 41,062, in the first year; of € 30,327 and € 84,026, in the
second, and of € 57,269 and € 126,660 in the third year derived from two reasons:
preventing new events in patients at risk and from averting follow-up in patients at
no risk, respectively. CONCLUSIONS: Potential cost savings derived from prevent-
ing new events and unnecessary follow-up may overcome the costs of introducing
the genetic testing for HCM, ARVC, LQTS, BrS and CPVT in the Spanish NHS.
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OBJECTIVES: Cirrhosis and its complications, such as hepatic encephalopathy (HE)
are the sixth cause of general mortality in Mexico. The objective is to update costs,
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time horizon and resources usage from a previous cost-effectiveness study for
medications used to treat hepatic encephalopathy from the Mexican Institute of
Social Security (IMSS) perspective and to complement it with a budget impact
analysis. METHODS: CE analysis of treatments used for acute HE, based in a deci-
sion tree model, and considering a horizon of 10 days. Alternatives available at the
IMSS are: lactulose, L-ornithine L-aspartate (LOLA), neomycin and alpha (a)poly-
morph rifaximin (the new alternative). Percentage of patients with improvement in
signs and symptoms of HE was the effectiveness measure and s based on available
published studies(Huang 2007 and Qian 2009). Only direct medical costs were con-
sidered and obtained from IMSS. Univariated sensitivity analysis, using pricing
discounts and effectiveness were performed and budget impact simulations were
developed. RESULTS: LOLA US$4024, lactulose US$4032, neomycin US$4060 and
rifaximin US $4039 final costs. In relation to effectiveness, the percentage of pa-
tients who presented improved signs and symptoms for each alternative is as
follows: lactulose and LOLA 55%, neomycin 64% and rifixamin 90%. Cost effective-
ness ratios are: lactulose US$7331, LOLA $7316, neomycin US$6344 and rifixamin
US$4488. The incremental cost effectiveness analysis indicates that LOLA and neo-
mycin are surpassed by lactulose and rifaximin, which are located on the efficiency
line. For the sensitivity analysis with one hospitalization day reduced due to the
improved efficacy, rifaximin was the dominating alternative. If lactulose and neo-
mycin are substituted by rifaximin in the estimated population(6,194 to 21,680
potential range of patients with HE in the Mexican Health System), the budget
impact shows savings equivalent to 77.74 y 72.36%, respectively. CONCLUSIONS:
Alpha (a) polymorph rifaximin is a highly cost effective alternative for treating
acute HE from an institutional perspective in México.
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OBJECTIVES: To estimate the budgetary impact of RRMS treatment from the per-
spective of the NHS in Spain (valued Euros-2011), in order to determine which
treatment is most efficient from the payer’s perspective.METHODS: IMS sales data
for multiple sclerosis drugs were used to estimate the total number of patients
treated with each of the drugs used during 2011. The number of patients receiving
treatment was calculated from the yearly cost of each treatment per patient (ex-
factory price excluding VAT) because IMS presents total sales expressed as ex-
factory price, which means that the yearly cost of the drug expressed as ex-factory
price must be used to estimate the number of patients from the IMS sales data.
Although there are clear differences in the effectiveness of the treatments used,
these differences do not always explain differences in prices (higher incremental
costs). RESULTS: Total expenditure in Spain in 2011 was €259 million. Among the
patients, 47% were treated with interferon beta-1a, 27% with interferon beta-1b,
16% with glatiramer acetate and 10% with natalizumab. In the unlikely event that
all patients had used interferon beta-1a in Spain, total expenditure would have
been between -10% and 6.3%, depending on the drug used. If interferon beta 1b
had been used by all patients, the total savings in Spain during 2011 would have
been over 12.5%. Nonetheless, the greatest savings (15% of total expenditure)
would have been achieved if all patients had been treated with glatiramer acetate.
CONCLUSIONS: Despite the limitations of the study (only direct drug costs were
considered and the number of patients receiving treatment was extrapolated) this
methodology may aid decision-making by policy makers, especially in times of
economic difficulty, by showing which medication is more efficient.
PND15
COST-EFFECTIVENESS OF BUCCOLAM® (LICENSED OROMUCOSAL MIDAZOLAM)
COMPARED TO BENZODIAZEPINES FOR THE TREATMENT OF ACUTE
PROLONGED EPILEPTIC SEIZURES IN GERMANY
Lee D, Gladwell D, Batty A, Brereton NJ
BresMed, Sheffield, UK
OBJECTIVES:BUCCOLAM (oromucosal midazolam) is approved for the treatment of
prolonged, acute, convulsive seizures in children and was the first product to re-
ceive a Paediatric-Use Marketing Authorisation (PUMA) in September 2011. The
product label includes use by parents and other carers such as teachers. Current
care in Germany for first line treatment consists mainly of rectal diazepam with
some use of buccal lorazepam, clonazepam and chloral hydrate. Some non-family
carers can be reluctant to administer these products due to concerns about social
acceptability, dignity or labelling issues. A decision tree model has been developed
to assess the cost of BUCCOLAM compared to current care for prolonged acute
convulsive seizures initially occurring in the community setting. METHODS: The
model evaluates costs along the treatment pathway when a child has a seizure
including whether or not carers administer treatment, whether an ambulance is
required and whether or not patients are taken to hospital and require an inpatient
stay. Data were obtained from a variety of sources including clinical effectiveness
estimates from McIntyre et al. 2005, and a Delphi panel. Costs were taken from
published sources. Estimates of the total eligible population were taken from epi-
lepsy prevalence data and the Delphi panel. RESULTS: Over one year, compared to
the mix of treatments representing current care, BUCCOLAM showed a reduction
in per patient costs of €3,469. Compared to treatment with rectal diazepam alone,
the most commonly used treatment, BUCCOLAM showed a cost reduction of
€3,533. It was expected that36,000 patients would be eligible. At an uptake of 20%
BUCCOLAM would reduce health care expenditure by €19.4 million in the first year.
CONCLUSIONS: Treatment with BUCCOLAM is cost-saving compared to current
care and treatment with rectal diazepam through a reduction in the need for am-
bulance call-outs and hospital stays.
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OBJECTIVES: Epilepsy is one of the most common chronic neurological disorders in
the world; therefore it is associated with substantial use of medical resources in
health institutions. Approximately 60% of patients with epilepsy suffer from par-
tial-onset seizures (POS), and among these, an estimated 30% have refractory dis-
ease. The objective of this study was to analyze the cost-effectiveness of lacos-
amide (LCM), a newer anti-epileptic drug (AED), versus second generation AEDs in
patients with refractory POS. METHODS: We conducted an economic evaluation,
using lamotrigine (LTG) 300 mg/day and topiramate (TPM) 200 mg/day as compar-
ators for LCM 200 and 400 mg/day. The perspective was the Mexican Social Security
Institute, in accordance with Mexican guidelines for Economic Evaluations. The
model included the cost of drug acquisition and management of adverse events
(AE) during the titration and 12 weeks of maintenance. Resource use associated
with AEs was defined according to the information gathered in a Delphi Panel. The
efficacy measure was the50% responder rate; i.e., the percentage of patients who
showed a 50% decrease in seizure frequency from baseline. An indirect compar-
ison was made. RESULTS: The adjusted response rates were 33% for LCM 200
mg/day (34% unadjusted), 39% LCM 400 mg/day (41% unadjusted), 24% for LTG (20%
unadjusted) and 31% for TPM (27% unadjusted). Costs per patient considering the
adjustment was MX$6,872, $7,836, $6,954 and $6,485 for LCM 200 mg, LCM 400 mg,
LTG and TPM, respectively. The cost per responder was lower for LCM 200 and 400
mg/day ($20,825 and $20,093, respectively) than TPM and LTG ($20,918 and $28,974,
respectively). Considering unadjusted data, LCM 200 and 400 mg/day had greater
differential in costs per responder compared with TPM or LTG. CONCLUSIONS:
From a Mexican perspective, lacosamide represents a cost-effective treatment op-
tion for patients with POS. Sponsored by UCB.
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OBJECTIVES: Controlled trials have found therapeutic plasma exchange (TPE) and
intravenous immunoglobulin (IVIg) infusion therapy to be equally efficacious in
treating Guillain-Barré syndrome (GBS). Due to increases in the price of IVIg com-
pared to human serum albumin (HSA), used as a replacement fluid in TPE, direct
hospital-level expenditures for TPE and IVIg for meaningful cost-differences be-
tween these treatments were exemined for Turkey. METHODS: Cost were calcu-
lated with Hacettepe University Hospital procedures for one cycle IVIg and TPE.
One cycle were defined for IVIg and TPE as 5 days and 5 series, respectively. A model
was developed which allows hospitals to input cost and reimbursement amounts
for both IVIg and TPE with HSA that results in real-time valuations of these inter-
ventions. Reimbursement amounts were obtained from publicly available Social
Security Institution (SGK) data resources to determine payment rates for TPE and
IVIg. Only direct cost and payer perspective were used for the calculation.
RESULTS: The direct cost of IVIg infusion sessions totaling 140,0 grams for 5 days
was 18,841 TL compared to a series of five TPE procedures, which had direct costs of
6,529 TL.CONCLUSIONS: In GBS patients, direct costs of IVIg therapy are more than
twice that of TPE. Given equivalent efficacy and similar severity and frequencies of
adverse events, TPE appears to be a less expensive first-line therapy option for
treatment of patients with GBS for Turkey.
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OBJECTIVES: To collate the published evidence evaluating economic burden of
co-morbidities in patients with Parkinson’s disease (PD) in Germany. METHODS: A
systematic search of electronic literature databases (Embase® and MEDLINE®) was
conducted from January 2001 to June 2012 to identify economic studies in English
evaluating co-morbidities in patients with PD in Germany. RESULTS: Four studies
of the 267 citations retrieved met the pre-defined inclusion criteria. During 2000-
2002, direct costs were higher in patients with dyskinesias and/or motor fluctua-
tions (€3300 [€4630]) or dementia (€3110 [€5610]) than patients without motor com-
plications (€1450 [€3760]) or dementia (€1530 [3460]). However, indirect costs were
higher for patients without dementia (€3780 [€6870]) than patients with dementia
(€1080 [€4110]). In 2006, daily total costs and PD drug treatment costs decreased
significantly in patients with dementia (€7.3 [7.3]; p0.05) and depression (€6.6 [5.8];
p0.05) than patients without dementia (€9.3 [13.9]) and depression (€7.6 [6.8]),
respectively. The decrease in the costs observed across patients presenting with
these co-morbidities may be attributed to the inadequate treatment of depression
or dementia among patients with PD. In 2009, direct costs demonstrated a signifi-
cant increase in patients with dyskinesia (€16,544 vs. €11,322; p0.003), dementia
(€21,142 vs. €10,619; p0.001), depression (€15,904 vs. €8826; p0.001), or psychosis
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